<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460334</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Kaposi Sarcoma as a Possible Cutaneous Adverse Effect of ChAdOx1 nCov-19 Vaccine: A Case Report.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1168</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101168</ELocationID><Abstract><AbstractText>The COVID-19 pandemic prompted the rapid development of vaccines, including the ChAdOx1 nCov-19 (AstraZeneca) vaccine. While effective, adverse effects have been reported, including cutaneous manifestations. Kaposi sarcoma (KS), a vascular tumor linked to Kaposi sarcoma herpesvirus/human herpesvirus 8 (HHV-8), has seen increased detection during the pandemic. This study reports a case of classic cutaneous KS in a 79-year-old male following the first dose of the ChAdOx1 nCov-19 vaccine, without prior SARS-CoV-2 infection. The patient developed multiple reddish-blue papules on his legs and feet, confirmed as KS through histopathology. Treatment included radiotherapy and sequential chemotherapy with Doxorubicin. The potential reactivation of latent HHV-8 by the vaccine is explored through mechanisms involving the SARS-CoV-2 spike protein and adenovirus vector, which may induce immune responses and inflammatory pathways. Although establishing a direct causal link remains challenging, the case highlights the need for vigilance regarding KS reactivation post-vaccination. Further large-scale studies are warranted to elucidate the relationship between COVID-19 vaccines and latent virus reactivation, ensuring comprehensive safety assessments and informed public health decisions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan-Han</ForeName><Initials>YH</Initials><Identifier Source="ORCID">0000-0002-2981-2630</Identifier><AffiliationInfo><Affiliation>Division of General Practice, Department of Medical Education, Changhua Christian Hospital, Changhua 500209, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Tzu</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Education, China Medical University Hospital, Taichung 404327, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Shu-Han</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0009-0005-0425-1338</Identifier><AffiliationInfo><Affiliation>Division of General Practice, Department of Medical Education, Changhua Christian Hospital, Changhua 500209, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hui-Ju</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-0193-4687</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Changhua Christian Hospital, Changhua 500209, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402202, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AstraZeneca vaccine</Keyword><Keyword MajorTopicYN="N">ChAdOx1 nCov-19 vaccine</Keyword><Keyword MajorTopicYN="N">Kaposi sarcoma</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">vaccine adverse effect</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460334</ArticleId><ArticleId IdType="pmc">PMC11511428</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101168</ArticleId><ArticleId IdType="pii">vaccines12101168</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ramasamy M.N., Minassian A.M., Ewer K.J., Flaxman A.L., Folegatti P.M., Owens D.R., Voysey M., Aley P.K., Angus B., Babbage G. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396:1979–1993. doi: 10.1016/S0140-6736(20)32466-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32466-1</ArticleId><ArticleId IdType="pmc">PMC7674972</ArticleId><ArticleId IdType="pubmed">33220855</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization 2023 data.who.int, WHO Coronavirus (COVID-19) Dashboard &gt; Vaccines [Dashboard]  [(accessed on 6 August 2024)].  Available online:  https://data.who.int/dashboards/covid19/vaccines.</Citation></Reference><Reference><Citation>Rahmani K., Shavaleh R., Forouhi M., Disfani H.F., Kamandi M., Oskooi R.K., Foogerdi M., Soltani M., Rahchamani M., Mohaddespour M. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Front. Public Health. 2022;10:873596. doi: 10.3389/fpubh.2022.873596.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.873596</ArticleId><ArticleId IdType="pmc">PMC9459165</ArticleId><ArticleId IdType="pubmed">36091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengstu S., Beyene Berha A. Safety and efficacy of COVID-19 vaccine in Africa: Systematic review. Infect. Drug Resist. 2023;16:3085–3100. doi: 10.2147/IDR.S401074.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S401074</ArticleId><ArticleId IdType="pmc">PMC10202204</ArticleId><ArticleId IdType="pubmed">37222988</ArticleId></ArticleIdList></Reference><Reference><Citation>All UK—Spontaneous Reports Received between 04/01/21 and 16/06/21 for COVID-19 Vaccine Oxford University/AstraZeneca. COVID-19 Vaccine AstraZeneca Analysis. Government of United Kingdom; London, UK: 2021.  [(accessed on 6 August 2024)].  Available online:  https://assets.publishing.service.gov.uk/media/61e80216d3bf7f054db93895/FOI_21-1036-2.pdf.</Citation></Reference><Reference><Citation>Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024;74:229–263. doi: 10.3322/caac.21834.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21834</ArticleId><ArticleId IdType="pubmed">38572751</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschachler E. Chapter 128. Kaposi Sarcoma and Angiosarcoma. In: Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller A.S., Leffell D.J., Wolff K., editors. Fitzpatrick’s Dermatology in General Medicine. 8th ed. The McGraw-Hill Companies; New York, NY, USA: 2012.</Citation></Reference><Reference><Citation>Iftode N., Rădulescu M.A., Aramă Ș.S., Aramă V. Update on Kaposi sarcoma-associated herpesvirus (KSHV or HHV8)–review. Rom. J. Intern. Med. 2020;58:199–208. doi: 10.2478/rjim-2020-0017.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/rjim-2020-0017</ArticleId><ArticleId IdType="pubmed">32681788</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiee A., Amini M.J., Arabzadeh Bahri R., Jafarabady K., Salehi S.A., Hajishah H., Mozhgani S.-H. Herpesviruses reactivation following COVID-19 vaccination: A systematic review and meta-analysis. Eur. J. Med. Res. 2023;28:278. doi: 10.1186/s40001-023-01238-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-023-01238-9</ArticleId><ArticleId IdType="pmc">PMC10413536</ArticleId><ArticleId IdType="pubmed">37559096</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiee A., Teymouri Athar M.M., Amini M.J., Hajishah H., Siahvoshi S., Jalali M., Jahanbakhshi B., Mozhgani S.H. Reactivation of herpesviruses during COVID-19: A systematic review and meta-analysis. Rev. Med. Virol. 2023;33:e2437. doi: 10.1002/rmv.2437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2437</ArticleId><ArticleId IdType="pubmed">36880642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambarey H., Blumenthal M.J., Chetram A., Joyimbana W., Jennings L., Orrell C., Schäfer G. Reactivation of Kaposi’s sarcoma-associated herpesvirus (KSHV) by SARS-CoV-2 in non-hospitalised HIV-infected patients. EBioMedicine. 2024;100:104986. doi: 10.1016/j.ebiom.2024.104986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2024.104986</ArticleId><ArticleId IdType="pmc">PMC10850403</ArticleId><ArticleId IdType="pubmed">38306893</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Ortega J.I., Cibrian A.G.R., Martinez-Jaramillo E., Silva M.d.C.G. Sporadic Kaposi Sarcoma Following a COVID-19 Vaccine: Mere Coincidence or Something More? Cureus. 2024;16:e53925. doi: 10.7759/cureus.53925.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.53925</ArticleId><ArticleId IdType="pmc">PMC10924926</ArticleId><ArticleId IdType="pubmed">38465101</ArticleId></ArticleIdList></Reference><Reference><Citation>White E., Fazio N., Tourmouzis K., Ryu S., Finger P.T., Sassoon J., Keresztes R., Chou T., Kaplowitz K., Honkanen R. Unilateral conjunctival Classic Kaposi Sarcoma following a COVID 19 booster. Am. J. Ophthalmol. Case Rep. 2024;34:101986. doi: 10.1016/j.ajoc.2023.101986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajoc.2023.101986</ArticleId><ArticleId IdType="pmc">PMC11004082</ArticleId><ArticleId IdType="pubmed">38601193</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantanowitz L., Otis C.N., Dezube B.J. Immunohistochemistry in Kaposi’s sarcoma. Clin. Exp. Dermatol. 2010;35:68–72. doi: 10.1111/j.1365-2230.2009.03707.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2230.2009.03707.x</ArticleId><ArticleId IdType="pubmed">19874352</ArticleId></ArticleIdList></Reference><Reference><Citation>Radu O., Pantanowitz L. Kaposi sarcoma. Arch. Pathol. Lab. Med. 2013;137:289–294. doi: 10.5858/arpa.2012-0101-RS.</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2012-0101-RS</ArticleId><ArticleId IdType="pubmed">23368874</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Balc’h P., Pinceaux K., Pronier C., Seguin P., Tadié J.-M., Reizine F. Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients. Crit. Care. 2020;24:530. doi: 10.1186/s13054-020-03252-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03252-3</ArticleId><ArticleId IdType="pmc">PMC7453668</ArticleId><ArticleId IdType="pubmed">32859241</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolucci S., Cassaniti I., Novazzi F., Fiorina L., Piralla A., Comolli G., Bruno R., Maserati R., Gulminetti R., Novati S. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int. J. Infect. Dis. 2021;104:315–319. doi: 10.1016/j.ijid.2020.12.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.12.051</ArticleId><ArticleId IdType="pmc">PMC7833117</ArticleId><ArticleId IdType="pubmed">33359064</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni E., Cerati M., Finzi G., Lombardo M., Sessa F. COVID-19 and HHV8 first spotted together: An affair under electron microscopy. J. Eur. Acad. Dermatol. Venereol. 2021;35:e311–e312. doi: 10.1111/jdv.17123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.17123</ArticleId><ArticleId IdType="pmc">PMC8013213</ArticleId><ArticleId IdType="pubmed">33460479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitzenbichler F., Weber M., Salzberger B. Infection image: Reoccurrence of Kaposis sarcoma after SARS-CoV-2 mRNA vaccination in an HIV-infected patient. Infection. 2023;52:283–284. doi: 10.1007/s15010-023-02121-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02121-9</ArticleId><ArticleId IdType="pmc">PMC10811143</ArticleId><ArticleId IdType="pubmed">38055117</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkow P., Islas-Muñoz B., Carpio-Guadarrama D., Pérez-Padilla R. Exacerbation of Kaposi sarcoma after MVA-BN (Jynneos) vaccination in a person with HIV/AIDS. AIDS. 2024;38:129–130. doi: 10.1097/QAD.0000000000003717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003717</ArticleId><ArticleId IdType="pubmed">38061024</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelletti M., Taddeo A., Colombo E., Brambilla L., Bellinvia M., Pregliasco F., Villa M.L., Della Bella S. Immunogenicity and safety of seasonal influenza vaccination in patients with classic Kaposi’s sarcoma. J. Investig. Dermatol. 2012;132:2414–2421. doi: 10.1038/jid.2012.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2012.151</ArticleId><ArticleId IdType="pubmed">22622418</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Dai L., Barrett L., James J., Plaisance-Bonstaff K., Post S.R., Qin Z. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. Commun. Biol. 2021;4:682. doi: 10.1038/s42003-021-02220-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02220-z</ArticleId><ArticleId IdType="pmc">PMC8175744</ArticleId><ArticleId IdType="pubmed">34083759</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestić D., Custers J., Švec D., Majhen D. Human adenovirus type 26 infection mediated by αvβ3 integrin is caveolin-1-dependent. Microbiol. Spectr. 2022;10:e0109722. doi: 10.1128/spectrum.01097-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.01097-22</ArticleId><ArticleId IdType="pmc">PMC9430667</ArticleId><ArticleId IdType="pubmed">35924932</ArticleId></ArticleIdList></Reference><Reference><Citation>Polizzotto M.N., Uldrick T.S., Wang V., Aleman K., Wyvill K.M., Marshall V., Pittaluga S., O’Mahony D., Whitby D., Tosato G. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood J. Am. Soc. Hematol. 2013;122:4189–4198. doi: 10.1182/blood-2013-08-519959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-08-519959</ArticleId><ArticleId IdType="pmc">PMC3868925</ArticleId><ArticleId IdType="pubmed">24174627</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Soto R., Dissinger N.J., Damania B. Kaposi’s sarcoma-associated herpesvirus viral interleukin-6 signaling upregulates integrin β3 levels and is dependent on STAT3. J. Virol. 2020;94:e01384-19. doi: 10.1128/JVI.01384-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01384-19</ArticleId><ArticleId IdType="pmc">PMC7022358</ArticleId><ArticleId IdType="pubmed">31801855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory S.M., West J.A., Dillon P.J., Hilscher C., Dittmer D.P., Damania B. Toll-like receptor signaling controls reactivation of KSHV from latency. Proc. Natl. Acad. Sci. USA. 2009;106:11725–11730. doi: 10.1073/pnas.0905316106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0905316106</ArticleId><ArticleId IdType="pmc">PMC2710638</ArticleId><ArticleId IdType="pubmed">19564611</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>